Mr. Carlton is a proven medical device executive with over 20 years of experience leading neuromodulation and pelvic health efforts at multiple companies including Medtronic InterStim and Boston Scientific Neuromodulation. He has led firms from inception to exit, having sold Intelect Medical to Boston Scientific.
Professor Yoo’s life-long research spans multiple areas in neuromodulation including lower urinary function, obstructive sleep apnea, and chronic heart failure. He was previously at Case Western, USC, Duke, and now the University of Toronto, where he is Associate Professor at the Institute of Biomedical Engineering.
Mr. Carlton is an experienced leader in the medical device industry. In addition to his role as CEO at EBT Medical, he is Co-founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm focusing on companies in the medical device space. Prior to his role at EBT Medical, he was President and CEO of HUINNO Inc., a digital healthcare company focused on improving the management and cost of hypertension through wearable technology and software.
Mr. Carlton came to Boston Scientific via the acquisition of Intelect Medical, where he served as both Co-Founder and Vice President of Product Development. While at Boston Scientific Neuromodulation, Mr. Carlton held multiple positions including Director of New Therapy Development where he focused on pain, deep brain stimulation, overactive bladder, and more.
At the start of his career, he held various roles at Medtronic, co-inventing the InterStim™ tined lead and developing InterStim™ II for the treatment of overactive bladder. He also served as Director of Engineering at Texcel Medical (Cirtec Medical).
Holding over 50 patents around electrical stimulations products and therapies, Mr. Carlton has a dual BS in Biomedical Engineering and Engineering Mechanics from The John Hopkins University. He also holds an MBA from Boston University.
Mr. Madden joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio Manager with both portfolio and lead fundraising responsibilities. Following business school, he was promoted to Principal and became Partner in 2018.
Mr. Madden is focused on medical device and healthcare services investments and is actively engaged in the financing, strategy, operations and acquisitions of portfolio companies. His active investments include AcuFocus, BardyDx, CardioFocus, CSA Medical, Endotronix, Leiters, Solsys Medical (now Misonix (NASDAQ: MSON), Stimwave, and Ximedica.
Prior to SV, Mr. Madden worked at Testa, Hurwitz & Thibeault, in the Business Practice, Emerging Technology and Private Equity groups, supporting both venture capital funds and venture backed companies in business formations and financings, mergers and acquisitions, and venture capital fundraising. He holds a BA (with honors) from Colby College, and an MBA from Boston University (Beta Gamma Sigma).
Mr. Smith is co-founder and managing partner of Ignite Venture Studio, which develops brands to disrupt the ‘startup-quo’ by building and accelerating their performance to achieve success in collaboration with strategic partners. Additionally, he recently launched HONED™️ Vitamins, a subscription service personalized through metabolic testing, and Fluent Smart Exam™️, a first oto market device that make sit simple to conduct medical exams remotely and share them with a virtual care physician via your smartphone.
Before founding Ignite Venture Studios, Mr. Smith served the majority of his career in various senior leadership roles at Johnson & Johnson, the world’s largest and most diversified healthcare company. Most recently, he served as Company Group Chairman, North America and oversaw several divisions and brands including Tylenol®, Zyrtec®, Band-Aid Brand®, and Neutrogena®.
During his time at J&J, he developed a strong track record of building and marketing global brands, driving insight-driven innovations, leading strategic business turnarounds, and delivering profitable growth.
Mr. Stiff joined Genesys Capital in 2002, became partner at the firm in 2007, and has served as Managing Director since 2016. During his tenure with Genesys, he has been responsible for investments in nine early stage portfolio companies that cross a multitude of clinical disciplines and technology areas.
Past board affiliations include Allostera Pharma Inc., gIcare Pharma Inc., Interface Biologics, Inc., Matregen Corp, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., StemPath Inc., Therapeutic Monitoring Systems Inc., and Zelos Therapeutics Inc.
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a BS (Honors) from Queen’s University and an MBA from the Rotman School of Management.
Professor Yoo has spent nearly 3 decades researching diverse areas of peripheral nerve stimulation therapies, such as neural control of lower urinary function, obstructive sleep apnea, and chronic heart failure.
In addition to academic research, Dr. Yoo has worked on a number of projects within the medical device space working with such companies as Imthera Medical Inc, Microtransponder Inc., Ethicon Endosurgery, Boston Scientific Corporation, and Nuviant Medical.
Prior to joining the University of Toronto in 2012, Dr. Yoo worked both as a post-doctoral research associate and assistant research professor at Duke University under Warren Grill. Dr. Yoo received his BASc from the University of Toronto in Engineering Science (Biomedical Option), MS in Biomedical Engineering from the University of Southern California, and PhD from Case Western Reserve University in Biomedical Engineering.
Beyond his experienced background as an entrepreneur, Dr. John is the sole inventor on the first patents for statistical closed-loop neurostimulation which were licensed into Neuropace’s FDA approved treatment for epilepsy. He is a co-inventor in an EEG-based hearing assessment technology acquired by Bio-logic Systems Corp. This technology became the company’s best-selling product before its acquisition by Natus.
He holds 85+ patents and has been an IP strategy consultant in the areas of neurostimulation, neurodiagnostics, wireless power transmission, and renal nerve ablation. As Chief Scientific Officer for AngelMed, he helped obtain FDA approval of the world’s first implantable heart-attack detector. In addition, he has led publication, clinical trial design, and market access strategies.
Dr. John has lectured on medical commercialization at the IBBME (University of Toronto) since 2007. He holds an MSc in Psychiatry (McGill) and a PhD in Medical Science (University of Toronto).